These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30576794)
21. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population-based, Nested Case-control Study. Pontes C; Marsal JR; Elorza JM; Aragón M; Prieto-Alhambra D; Morros R Clin Ther; 2018 Feb; 40(2):270-283. PubMed ID: 29398161 [TBL] [Abstract][Full Text] [Related]
22. Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis. Guermazi A; Roemer FW; Kompel AJ; Diaz LE; Crema MD; Brown MT; Hickman A; Pixton GC; Viktrup L; Fountaine RJ; Burr A; Sherlock SP; West CR Osteoarthr Imaging; 2022; 2(3-4):. PubMed ID: 38343426 [TBL] [Abstract][Full Text] [Related]
23. Recent developments in the treatment of osteoarthritis with NSAIDs. Argoff CE Curr Med Res Opin; 2011 Jul; 27(7):1315-27. PubMed ID: 21561395 [TBL] [Abstract][Full Text] [Related]
24. Tanezumab for the treatment of osteoarthritis pain. Gondal FR; Bilal J; Kent Kwoh C Drugs Today (Barc); 2022 Apr; 58(4):187-200. PubMed ID: 35412532 [TBL] [Abstract][Full Text] [Related]
25. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Towheed T; Shea B; Wells G; Hochberg M Cochrane Database Syst Rev; 2000; (2):CD000517. PubMed ID: 10796384 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600 [TBL] [Abstract][Full Text] [Related]
27. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Watson MC; Brookes ST; Kirwan JR; Faulkner A Cochrane Database Syst Rev; 2000; (2):CD000142. PubMed ID: 10796306 [TBL] [Abstract][Full Text] [Related]
28. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Zeng C; Wei J; Persson MSM; Sarmanova A; Doherty M; Xie D; Wang Y; Li X; Li J; Long H; Lei G; Zhang W Br J Sports Med; 2018 May; 52(10):642-650. PubMed ID: 29436380 [TBL] [Abstract][Full Text] [Related]
29. Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model. Dong X; Li H; Pei M; Tan J; Chen G; Li S; Xie Z; Wang Q; Wang G; Chen YL; Wang C FEBS Open Bio; 2022 Jul; 12(7):1325-1335. PubMed ID: 35417079 [TBL] [Abstract][Full Text] [Related]
30. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Hale M; Tudor IC; Khanna S; Thipphawong J Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906 [TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
33. Nerve growth factor: an update on the science and therapy. Seidel MF; Wise BL; Lane NE Osteoarthritis Cartilage; 2013 Sep; 21(9):1223-8. PubMed ID: 23973134 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of duloxetine by prior NSAID use in the treatment of chronic osteoarthritis knee pain: A post hoc subgroup analysis of a randomized, placebo-controlled, phase 3 study in Japan. Enomoto H; Fujikoshi S; Tsuji T; Sasaki N; Tokuoka H; Uchio Y J Orthop Sci; 2018 Nov; 23(6):1019-1026. PubMed ID: 30126675 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899 [TBL] [Abstract][Full Text] [Related]
36. The causes and effects of socio-demographic exclusions from clinical trials. Bartlett C; Doyal L; Ebrahim S; Davey P; Bachmann M; Egger M; Dieppe P Health Technol Assess; 2005 Oct; 9(38):iii-iv, ix-x, 1-152. PubMed ID: 16181564 [TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain. Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378 [TBL] [Abstract][Full Text] [Related]